Ang Lifesciences India Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of ANG Lifesciences India Ltd is ₹ 26.88 as of 15 May 15:30 . The P/E Ratio of ANG Lifesciences India Ltd changed from 6 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 years The Market Cap of ANG Lifesciences India Ltd changed from ₹ 243.2 crore on March 2022 to ₹ 29.67 crore on March 2025 . This represents a CAGR of -40.90% over 4 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 years The revenue of ANG Lifesciences India Ltd for the Dec '25 is ₹ 18.89 crore as compare to the Sep '25 revenue of ₹ 26.18 crore. This represent the decline of -27.85% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of ANG Lifesciences India Ltd for the Dec '25 is ₹ -2.53 crore as compare to the Sep '25 ebitda of ₹ 0.2 crore. This represent the decline of -1365% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of ANG Lifesciences India Ltd changed from ₹ -3.07 crore to ₹ -4.75 crore over 7 quarters. This represents a CAGR of 28.33% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of ANG Lifesciences India Ltd changed from 2.61 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About ANG Lifesciences India Ltd

ANG Lifesciences India Limited was originally incorporated as a Private Limited Company with the name 'ANG Lifesciences India Private Limited' on June 14, 2006.
On conversion into Public Limited Company, the name was changed to ANG Lifesciences India Limited on March 02, 2010.
The Company further converted into Private Limited Company and the name of the Company was changed to 'ANG Lifesciences India Private Limited' on September 22, 2010.
Subsequently, on conversion into Public Limited Company, the name again changed to 'ANG Lifesciences India Limited' on May 18, 2016. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of Sterile Dry Powder Injection Vials.
In 2008-09, the Company started its commercial production.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of ANG Lifesciences India Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, ANG Lifesciences India Ltd or Parmax Pharma Ltd?

Market cap of ANG Lifesciences India Ltd is 35 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of ANG Lifesciences India Ltd and Parmax Pharma Ltd?

The stock performance of ANG Lifesciences India Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ANG Lifesciences India Ltd and Parmax Pharma Ltd?

As of May 17, 2026, the ANG Lifesciences India Ltd stock price is INR ₹26.88. On the other hand, Parmax Pharma Ltd stock price is INR ₹31.17.

How do dividend payouts of ANG Lifesciences India Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of ANG Lifesciences India Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.